(Q38199328)

30 August 2017

title

Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancer (English)

1 reference

30 August 2017

1 reference

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24667713%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Fabrice André

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24667713%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Emiliano Calvo

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24667713%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Alain Ravaud

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24667713%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

author name string

M Aapro

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24667713%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

K Blackwell

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24667713%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

M Jahanzeb

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24667713%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

K Papazisis

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24667713%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

K Pritchard

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24667713%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

publication date

1 April 2014

1 reference

30 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24667713%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

volume

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24667713%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24667713%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

page(s)

763-773

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24667713%20AND%20SRC:MED&resulttype=core&format=json

Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163.

11 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU021

Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU021

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU021

Everolimus for advanced pancreatic neuroendocrine tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU021

Common toxicities of mammalian target of rapamycin inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU021

Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU021

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU021

Everolimus: side effect profile and management of toxicities in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU021

1st International consensus guidelines for advanced breast cancer (ABC 1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU021

Metabolic complications with the use of mTOR inhibitors for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU021

mTOR signaling in growth control and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU021

Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU021

Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU021

Managing stomatitis in patients treated with Mammalian target of rapamycin inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU021

Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU021

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU021

Oral adverse events associated with tyrosine kinase and mammalian target of rapamycin inhibitors in renal cell carcinoma: a structured literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU021

Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU021

A review of oral toxicity associated with mTOR inhibitor therapy in cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU021

Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU021

Clinical presentation and management of mTOR inhibitor-associated stomatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU021

Natural history, management and pharmacokinetics of everolimus-induced-oral ulcers: insights into compliance issues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU021

Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU021

Mammalian target of rapamycin (mTOR) inhibitor-associated non-infectious pneumonitis in patients with renal cell cancer: predictors, management, and outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU021

Emergent toxicities associated with the use of mTOR inhibitors in patients with advanced renal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU021

Severe hypertriglyceridemia and pancreatitis: presentation and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU021

Toxicities of targeted therapy and their management in kidney cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU021

The influence of comorbidities on overall survival among older women diagnosed with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU021